Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma - guidance (TA641)

Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (CHP) is recommended as an option for untreated systemic anaplastic large cell lymphoma in adults.

National Institute for Health and Care Excellence